Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Dare Bioscience (DARE) PT Lowered to $11 at Brookline Capital Markets
August 18, 2025 3:59 PM EDTBrookline Capital Markets analyst Kemp Dolliver lowered the price target on Dare Bioscience (NASDAQ: DARE) to $11.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "Darés Q2 update was less informative than we expected. The company continues with plans to bring Sildenafil... More
